Buciu Ionut Cezar, Tieranu Eugen Nicolae, Pircalabu Andreea Stefania, Zlatian Ovidiu Mircea, Donoiu Ionut, Militaru Constantin, Militaru Sebastian, Militaru Cristian
Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Department of Cardiology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Biomedicines. 2024 Sep 23;12(9):2159. doi: 10.3390/biomedicines12092159.
Cardiovascular diseases are the leading cause of mortality worldwide, with a significant impact on socioeconomic aspects. Various biomarkers have been studied in relation to the diagnosis, progression, and prognosis of atherosclerotic disease, with lipoprotein (a) [Lp (a)] standing out as an important predictor of cardiovascular risk. This observational study aimed to clarify the association between Lp (a) levels and the severity of significant multivessel coronary lesions in acute myocardial infarction (AMI) patients. Conducted at the Clinical Emergency County Hospital of Craiova, Romania, the study involved 256 young patients divided into two groups based on Lp (a) levels: Group A (Lp (a) < 30 mg/dL) and Group B (Lp (a) ≥ 30 mg/dL). Patients included young adults up to 55 years for males and 60 years for females, excluding those with familial hypercholesterolemia. The study revealed a significant association between elevated Lp (a) levels and the presence of multivessel coronary lesions. Patients with Lp (a) concentrations ≥ 30 mg/dL exhibited a higher prevalence of multivessel disease compared to those with lower levels. The findings suggest that elevated Lp (a) levels are a crucial biomarker for the risk of coronary artery disease, particularly in young patients with AMI. The study emphasizes the need for aggressive lipid management strategies and personalized treatment approaches, considering the significant role of Lp (a) in atherosclerosis and AMI. Lipoprotein A levels above 30 mg/dL are associated with a higher prevalence of multivessel coronary lesions. Multivariate analysis revealed that higher Lp (a) levels and lower HDL levels are linked to an increased risk of multivessel coronary lesions.
心血管疾病是全球主要的死亡原因，对社会经济方面有重大影响。关于动脉粥样硬化疾病的诊断、进展和预后，人们已经研究了各种生物标志物，其中脂蛋白(a) [Lp(a)]是心血管风险的重要预测指标。这项观察性研究旨在阐明急性心肌梗死(AMI)患者Lp(a)水平与严重多支冠状动脉病变严重程度之间的关联。该研究在罗马尼亚克拉约瓦县临床急救医院进行，纳入了256名年轻患者，根据Lp(a)水平分为两组：A组(Lp(a) < 30 mg/dL)和B组(Lp(a)≥30 mg/dL)。患者包括年龄在55岁以下的男性和60岁以下的女性，不包括家族性高胆固醇血症患者。研究发现Lp(a)水平升高与多支冠状动脉病变的存在之间存在显著关联。与Lp(a)水平较低的患者相比，Lp(a)浓度≥30 mg/dL的患者多支血管疾病的患病率更高。研究结果表明，Lp(a)水平升高是冠状动脉疾病风险的关键生物标志物，尤其是在患有AMI的年轻患者中。该研究强调了积极的血脂管理策略和个性化治疗方法的必要性，考虑到Lp(a)在动脉粥样硬化和AMI中的重要作用。Lp(a)水平高于30 mg/dL与多支冠状动脉病变的较高患病率相关。多变量分析显示，较高的Lp(a)水平和较低的HDL水平与多支冠状动脉病变风险增加有关。
